Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Modena – page 15

387 clinical trials in Modena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Modena at a glance
387
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

387 trials in Modena

Open in trial search

Metastatic renal cell carcinoma

Not yet recruiting

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Amyotrophic lateral sclerosis

Not yet recruiting

Randomized Placebo‑Controlled Trial of Colchicine to Slow Disease Progression in Adults with Amyotrophic Lateral Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Squamous cell carcinoma of skin

Not yet recruiting

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione GONO Plus

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Transitional cell carcinoma metastatic

Not yet recruiting

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Hepatocellular carcinoma+5

Not yet recruiting

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:Dualitybio Inc.

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zampilimab
  • Sponsor:Chiesi Farmaceutici S.p.A.

Hereditary haemochromatosis

Not yet recruiting

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vamifeport trihydrochloride
  • Sponsor:CSL Behring LLC

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Modena

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical trials exploring treatments for pulmonary fibrosis and severe asthma, evaluating novel therapies aimed at improving lung function and patient outcomes.

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
  • High-Risk Asthma

Research focuses on evaluating forced vital capacity changes and reducing asthma exacerbations.

02 Autoimmune Conditions

Groundbreaking studies examining treatments for systemic sclerosis and related autoimmune disorders, with emphasis on innovative biological therapies.

  • Diffuse Cutaneous Systemic Sclerosis
  • Systemic Autoimmune Rheumatic Diseases
  • Interstitial Lung Diseases

Studies aim to improve skin sclerosis and manage associated complications.

03 Oncology Research

Advanced trials investigating treatments for various cancers, including gastric cancer and hematological malignancies.

  • HER2-positive Gastric Cancer
  • Follicular Lymphoma
  • Metastatic Renal Cell Carcinoma

Focus on immunotherapy combinations and targeted treatments for better patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.